Study: NCT04518410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bamlanivimab 7000mg
Description: Administered by single IV infusion. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-196+BRII-198
Description: 1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442 (IV)
Description: 300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442 (IM)
Description: Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNG001
Description: 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: 200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986414 + BMS-986413
Description: Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185 (3,840 Units/kg)
Description: Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185 (3,840 Units/kg)
Description: Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185 (3,840 Units/kg)
Description: Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185 (10,240 Units/kg)
Description: Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CASIRIVIMAB + IMDEVIMAB
Description: 600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CASIRIVIMAB + IMDEVIMAB
Description: 600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Bamlanivimab 7000mg
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Bamlanivimab 700mg
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BRII-196+BRII-198
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.